Download PDF
neuroreha 2018; 10(02): 90-94
DOI: 10.1055/a-0596-6696
Aus der Praxis
© Georg Thieme Verlag KG Stuttgart · New York

Psychiatrische Begleiterkrankungen im Rahmen einer Parkinson-Demenz

Lina Riedl
,
Urban M. Fietzek
Further Information

Publication History

Publication Date:
08 June 2018 (online)

    Permissions and Reprints

Zusammenfassung

Im späteren Verlauf der Parkinson-Krankheit besteht ein hohes Risiko, neben der charakterisierenden motorischen Symptomatik beeinträchtigende kognitive Funktionsstörungen zu entwickeln. Dieser Störungskomplex kann maßgeblich den klinischen Verlauf bei Patienten in fortgeschrittenen Krankheitsstadien bestimmen. Der Artikel umschreibt knapp das pathophysiologische Konzept kognitiver Beeinträchtigungen bei Parkinson. Er benennt relevante Differenzierungen, die Wege zur Diagnose und aktuelle therapeutische Herangehensweisen.

 

  • Literatur

  • 1 Aarsland D, Andersen K, Larsen JP. et al. Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch. Neurol. 2003; 60: 387-392
    CrossrefPubMedGoogle Scholar
  • 2 Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2009; 24: 2175-2186
    CrossrefPubMedGoogle Scholar
  • 3 Aarsland D, Bronnick K, Williams-Gray C. et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010; 75: 1062-1069
    CrossrefPubMedGoogle Scholar
  • 4 Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107-110
    CrossrefPubMedGoogle Scholar
  • 5 Braak H, Del Tredici K, Rüb U. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211
    CrossrefPubMedGoogle Scholar
  • 6 Clarenbach P. Parkinson’s disease and sleep. J Neurol 2000; 247 (Suppl. 04) IV/20-23
    PubMedGoogle Scholar
  • 7 Cummings JL, Mega M, Gray K. et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314
    CrossrefPubMedGoogle Scholar
  • 8 Diagnostisches und statistisches Manual psychischer Störungen DSM-5®. Göttingen: Hogrefe; 2015
    Google Scholar
  • 9 DIMDI. ICD-10-GM. Version 2018. Im Internet: www.dimdi.de/static/de/klassi/icd-10-gm/kodesuche/onlinefassungen/htmlgm2018/index.htm Stand: 26.03.2018
    Google Scholar
  • 10 Dirnberger G, Jahanshahi M. Executive dysfunction in Parkinson’s disease: A review. J Neuropsychol 2013; 7: 193-224
    CrossrefPubMedGoogle Scholar
  • 11 Dooneief G, Mirabello E, Bell K. et al. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992; 49: 305-307
    CrossrefPubMedGoogle Scholar
  • 12 Dujardin K, Sockeel P, Devos D. et al. Characteristics of apathy in Parkinson’s disease. Mov Disord 2007; 22: 778-784
    CrossrefPubMedGoogle Scholar
  • 13 Emre M, Aarsland D, Albanese A. et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509-2518
    CrossrefPubMedGoogle Scholar
  • 14 Emre M, Aarsland D, Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2007; 22: 1689-1707 quiz 1837
    CrossrefPubMedGoogle Scholar
  • 15 Etgen T, Sander D, Bickel H. et al. Mild cognitive impairment and dementia: The importance of modifiable risk factors. Dtsch Arzteblatt Int 2011; 108: 743-750
    Google Scholar
  • 16 Falkai. et al. Diagnostisches und statistisches Manual psychischer Störungen DSM-5® . Göttingen: Hogrefe; 2015
    Google Scholar
  • 17 Ffytche DH, Creese B, Politis M. et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol 2017; 13: 81-95
    CrossrefPubMedGoogle Scholar
  • 18 Freundt EC, Maynard N, Clancy EK. et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol 2012; 72: 517-524
    CrossrefPubMedGoogle Scholar
  • 19 George S, Rey NL, Reichenbach N. et al. α-Synuclein: The long distance runner. Brain Pathol Zurich Switz 2013; 23: 350-357
    Google Scholar
  • 20 Goedert M, Spillantini MG, Del Tredici K. et al. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9: 13-24
    CrossrefPubMedGoogle Scholar
  • 21 Goedert M, Masuda-Suzukake M, Falcon B. Like prions: The propagation of aggregated tau and α-synuclein in neurodegeneration. Brain J Neurol 2017; 140: 266-278
    CrossrefPubMedGoogle Scholar
  • 22 Goldman SM, Quinlan PJ, Ross GW. et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71: 776-784
    CrossrefPubMedGoogle Scholar
  • 23 Hansmann J, Ceballos-Baumann A. Gibt es eine Pharmakotherapie von „herausforderndes Verhalten“?. Nervenheilkunde 2015; 34: 161-166
    Article in Thieme ConnectGoogle Scholar
  • 24 Hely MA, Morris JG, Reid WG. et al. Sydney Multicenter Study of Parkinson’s disease: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199
    CrossrefPubMedGoogle Scholar
  • 25 Hely MA, Reid WGJ, Adena MA. et al. The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844
    CrossrefPubMedGoogle Scholar
  • 26 Hindmarch I, Lehfeld H, de Jongh P. et al. The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 1998; 9 (Suppl. 02) 20-26
    PubMedGoogle Scholar
  • 27 Holden SK, Jones WE, Baker KA. et al. Outcome measures for Parkinson’s disease dementia: A systematic review. Mov Disord Clin Pract 2016; 3: 9-18
    PubMedGoogle Scholar
  • 28 Klein C, Schlossmacher MG. The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2006; 2: 136-146
    PubMedGoogle Scholar
  • 29 Lenka A, Herath P, Christopher R. et al. Psychosis in Parkinson’s disease: From the soft signs to the hard science. J Neurol Sci 2017; 379: 169-176
    CrossrefPubMedGoogle Scholar
  • 30 Litvan I, Goldman JG, Tröster AI. et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement disorder society task force guidelines. Mov Disord Off J Mov Disord Soc 2012; 27: 349-356
    CrossrefPubMedGoogle Scholar
  • 31 Mayeux R. Depression in the patient with Parkinson’s disease. J Clin Psychiatry 1990; 51 (Suppl) 20-23 discussion 24–25
    PubMedGoogle Scholar
  • 32 Mayeux R, Denaro J, Hemenegildo N. A population-based investigation of parkinson’s disease with and without dementia: Relationship to age and gender. Arch Neurol 1992; 49: 492-497
    CrossrefPubMedGoogle Scholar
  • 33 McKeith I. Dementia with Lewy bodies and Parkinson’s disease with dementia: Where two worlds collide. Pract Neurol 2007; 7: 374-382
    CrossrefPubMedGoogle Scholar
  • 34 Memory Clinic. CERAD-Plus – Die Neuropsychologische Testbatterie CERAD-Plus. Im Internet: www.memoryclinic.ch/de/main-navigation/neuropsychologen/cerad-plus/ Stand: 26.03.2018
    Google Scholar
  • 35 Morris JC, Heyman A, Mohs RC. et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989; 39: 1159-1165
    CrossrefPubMedGoogle Scholar
  • 36 Petzinger GM, Fisher BE, McEwen S. et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol 2013; 12: 716-726
    CrossrefPubMedGoogle Scholar
  • 37 Poewe W, Luginger E. Depression in Parkinson’s disease: Impediments to recognition and treatment options. Neurology 1999; 52: S2-6
    CrossrefPubMedGoogle Scholar
  • 38 Poewe W. When a Parkinson’s disease patient starts to hallucinate. Pract Neurol 2008; 8: 238-241
    CrossrefPubMedGoogle Scholar
  • 39 Postuma RB, Anang J, Pelletier A. et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology 2017; 89: 1795-1803
    CrossrefPubMedGoogle Scholar
  • 40 Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24: 653-659
    PubMedGoogle Scholar
  • 41 Rolinski M, Fox C, Maidment I. et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012; CD006504
    PubMedGoogle Scholar
  • 42 Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356-1364
    CrossrefPubMedGoogle Scholar
  • 43 Sixel-Döring F, Trautmann E, Mollenhauer B. et al. Rapid eye movement sleep behavioral events: A new marker for neurodegeneration in early Parkinson disease?. Sleep 2014; 37: 431-438
    CrossrefPubMedGoogle Scholar
  • 44 Skorvanek M, Goldman JG, Jahanshahi M. et al. Global scales for cognitive screening in Parkinson’s disease: Critique and recommendations. Mov Disord 2018; 33: 208-218
    CrossrefPubMedGoogle Scholar
  • 45 Speelman AD, van de Warrenburg BP, van Nimwegen M. et al. How might physical activity benefit patients with Parkinson disease?. Nat Rev Neurol 2011; 7: 528-534
    CrossrefPubMedGoogle Scholar
  • 46 Stocchi F, Abbruzzese G, Ceravolo R. et al. Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology 2014; 83: 215-220
    CrossrefPubMedGoogle Scholar
  • 47 Svenningsson P, Westman E, Ballard C. et al. Cognitive impairment in patients with Parkinson’s disease: Diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11: 697-707
    CrossrefPubMedGoogle Scholar
  • 48 Trenkwalder C, Kohnen R, Högl B. et al. Parkinson’s disease sleep scale: Validation of the revised version PDSS-2. Mov Disord 2011; 26: 644-652
    CrossrefPubMedGoogle Scholar
  • 49 Walker Z, Possin KL, Boeve BF. et al. Lewy body dementias. Lancet Lond Engl 2015; 386: 1683-1697
    Google Scholar
  • 50 Winner B, Jappelli R, Maji SK. et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011; 108: 4194-4199
    CrossrefPubMedGoogle Scholar
  • 51 Yesavage JA, Brink TL, Rose TL. et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982; 17: 37-49
    CrossrefPubMedGoogle Scholar